# ClinicalTrialEndpointAuditEscrow
### Autonomous Biopharmaceutical Licensing Milestone Escrow & ClinicalTrials.gov / FDA Primary Endpoint Consensus Adjudicator
**Protocol Standard**: GenLayer Intelligent Contract v0.2.1  
**Target Account**: [`metaremover`](https://github.com/metaremover)  
**Repository**: [https://github.com/metaremover/clinical-trial-endpoint-audit-escrow](https://github.com/metaremover/clinical-trial-endpoint-audit-escrow)  
**Execution Environment**: GenLayer Studio Testnet  
**Contract Address**: [`0x05aeFfE06ea65908223F747f722e6980b08eee0b`](https://explorer-studio.genlayer.com/address/0x05aeFfE06ea65908223F747f722e6980b08eee0b)  

---

## 1. Executive Summary & Biopharmaceutical Licensing Dilemma

In global biopharmaceutical licensing agreements, multinational pharmaceutical sponsors (e.g. Novartis, Roche, Pfizer) license drug candidates from early-stage biotechnology research institutes and oncology startups. These transactions obligate **Clinical Development Milestone Payments** (ranging from \$50M to \$500M+ per Phase 2/3 readout), contingent upon achieving pre-specified clinical endpoints:
1. **Primary Endpoint Success**: Statistically significant improvement in Progression-Free Survival (PFS), Overall Survival (OS), or Objective Response Rate (ORR) with pre-specified $p$-value ($p < 0.05$).
2. **Absence of Catastrophic Toxicity / Regulatory Holds**: Clean safety evaluation without FDA or EMA clinical holds.
3. **Regulatory Submission Acceptance**: Formal acceptance of Investigational New Drug (IND) or Biologics License Application (BLA).

### The Adjudication Dilemma
When clinical trial results read out:
- Pharmaceutical licensees routinely contest endpoint validity, statistical methodology, subgroup analyses, or patient population exclusions, refusing to disburse escrowed milestone capital.
- Biotechs with finite cash runways face 2 to 4 years of destructive litigation in Delaware Chancery Court or commercial arbitration, risking insolvency before their therapy reaches patients.
- Traditional smart contracts cannot ingest or interpret complex, semi-structured clinical protocols, biostatistical hazard ratios, or FDA regulatory correspondence.

### The GenLayer Intelligent Solution
`ClinicalTrialEndpointAuditEscrow` establishes an autonomous clinical escrow settlement court natively on GenLayer:
- Escrows licensing milestone capital backed 100% by native funds (`@gl.public.write.payable`).
- Restricts external evidence ingestion exclusively to authoritative trial registries and federal regulatory portals (`clinicaltrials.gov`, `fda.gov`, `ema.europa.eu`, `nih.gov`), eliminating SSRF and arbitrary URL spoofing.
- Executes multi-validator equivalence consensus via GenLayer Equivalence Principle (`gl.eq_principle.prompt_non_comparative` + `gl.nondet.web.render`) where all validators independently refetch official clinical protocol readouts and audit endpoints:
  - **ENDPOINT_MET**: Verifies primary endpoint achievement with statistical significance ($p < 0.05$) and no safety holds $\rightarrow$ Automatically disburses 100% milestone funds to the biotech recipient and refunds the claimant's dispute bond.
  - **CLAIM_REFUTED**: Frivolous assertion or trial failure ($p \ge 0.05$) $\rightarrow$ Slashes dispute bond to the sponsor's indemnity balance.
  - **Consensual Settlement**: Sponsor can approve milestone disbursement at any point prior to deadline.

---

## 2. Deterministic Protocol Architecture & State Machine

```
+-------------------------------------------------------------------------------+
|                       PROTOCOL STATE TRANSITION MACHINE                       |
+-------------------------------------------------------------------------------+

   [PHARMA SPONSOR: MILESTONE ESCROW]
              |
              v
   +----------------------+     Invalid Format     +-----------------------------+
   | Address & NCT ID     | ---------------------> | REVERT: [ERR_ADDR_FORMAT]   |
   | Sanitization Filter  |                        | REVERT: [ERR_STR_TOO_SHORT] |
   +----------------------+                        +-----------------------------+
              | Valid 42-char Hex & NCT ID
              v
   +----------------------+     Insufficient Funds +-----------------------------+
   | 100% Payable Escrow  | ---------------------> | REVERT: [ERR_MIN_ESCROW]    |
   | Verification Gate    |                        +-----------------------------+
   +----------------------+
              | Escrow Funded
              v
   +-----------------------------------------------------------------------------+
   | STATE: ACTIVE | milestone_escrow_amount = gl.message.value | milestones[id] |
   +-----------------------------------------------------------------------------+
              |
              +-------------------------------------------------+
              |                                                 |
              | Consensual Signoff                              | Clinical Trial Readout
              v                                                 v
   +----------------------+                        +-----------------------------+
   | approve_milestone_   |                        | submit_clinical_endpoint_   |
   | payout (Sponsor)     |                        | claim (Claimant + Bond)     |
   +----------------------+                        +-----------------------------+
              |                                                 |
              v                                                 v
   +----------------------+                        +-----------------------------+
   | Disburse Escrow to   |                        | SSRF & Host Whitelist Check |
   | Biotech Recipient    |                        | (clinicaltrials.gov, fda)   |
   +----------------------+                        +-----------------------------+
              |                                                 |
              v                                                 v
   +----------------------+                        +-----------------------------+
   | STATE: MILESTONE_    |                        | Multi-Validator LLM Consens |
   | ACHIEVED             |                        | (p < 0.05 & Safety Audit)   |
   +----------------------+                        +-----------------------------+
                                                                |
                                             +------------------+------------------+
                                             |                                     |
                                             v Endpoint Met (p < 0.05)             v Refuted / Failed
                                  +----------------------+               +-----------------------+
                                  | 100% Milestone to    |               | Slash Bond to         |
                                  | Biotech & Bond Back  |               | Sponsor Indemnity     |
                                  +----------------------+               +-----------------------+
                                             |                                     |
                                             v                                     v
                                  +----------------------+               +-----------------------+
                                  | STATE: MILESTONE_    |               | STATE: ACTIVE         |
                                  | ACHIEVED             |               | (Claim: CLAIM_REFUTED)|
                                  +----------------------+               +-----------------------+
```

---

## 3. Core Hardcore Security Protections & Steward Invariants

1. **100% Backed Payable Escrow**: Licensing milestones, top-ups, and audit bonds are funded strictly via `@gl.public.write.payable` reading `gl.message.value`.
2. **Zero Synthetic Genesis Liabilities**: Total Volume Locked strictly matches verified on-chain deposits. No phantom balances in `__init__`.
3. **Storage Dataclasses**: All numerical variables in `@allow_storage` dataclasses are strictly typed as `u256`.
4. **Strict SSRF & URL Whitelist**: External trial ingestion strictly limits target domains to official clinical registries (`clinicaltrials.gov`, `fda.gov`, `ema.europa.eu`, `nih.gov`). Explicitly rejects loopback IPs, numeric hosts, embedded credentials (`@`), and whitespace.
5. **Length-Prefixed Canonical Fingerprinting**: Eliminates delimiter and collision attacks using `L<len>:val|` format.
6. **Non-Admin Consensus Clock**: All milestone deadlines and 7-day timeout dispute periods evaluate strictly against consensus UTC timestamps (`datetime.datetime.now(datetime.timezone.utc).timestamp()`).
7. **Timeout Bond Safeguard**: Claimants can reclaim their dispute bond after a 7-day timeout if clinical registry endpoints become unreachable.
8. **Pull-Pattern Balance Recovery**: Failed native EVM disbursements automatically credit `claimable_balances[recipient]`. `withdraw_claimable()` optimistically zeroes the balance and restores it upon failure.
9. **Safe Fallback on Ingestion / Parsing Glitches (CRIT-01)**: If consensus JSON parsing or LLM response formatting errors occur, verdicts default strictly to `CLAIM_INCONCLUSIVE`, protecting claimant bonds from unjust slashing.
10. **Solvency Accounting Guarantee (CRIT-02)**: `total_volume_locked` is decremented strictly upon successful native transfer. Failed transfers retain TVL backing until funds are withdrawn via `withdraw_claimable()`, eliminating double decrements.
11. **Dispute State Locking (HIGH-01)**: Filing a dispute immediately transitions the milestone to `STATUS_DISPUTED`, locking the state and preventing front-running milestone payout approvals or premature expiration refunds.
12. **Prompt Sanitation Defense (HIGH-02)**: Strips HTML tags and script/style bloat via regex before prompt injection, preventing context truncation and false refutations.
13. **Dispute Deadline Enforcement (MED-03)**: Strictly verifies that claims are submitted before the milestone deadline (`now_utc <= milestone_deadline`).

---

## 4. Contract Methods & Public API

### State-Modifying Methods
- `create_clinical_milestone_escrow(biotech_recipient: str, trial_nct_id: str, target_primary_endpoint: str, duration_seconds: int)`: Creates a new licensing milestone escrow.
- `topup_milestone_escrow(milestone_id: str)`: Tops up escrow reserves for an active milestone.
- `approve_milestone_payout(milestone_id: str)`: Consensually disburses milestone funds to the biotech recipient.
- `claim_expired_unachieved_milestone(milestone_id: str)`: Refunds milestone collateral to sponsor if trial deadline elapses without achievement.
- `submit_clinical_endpoint_claim(milestone_id: str, registry_url: str, reported_p_value_bp: int, primary_endpoint_achieved: bool, nonce: str)`: Submits an official trial readout dispute.
- `adjudicate_clinical_endpoint_claim(claim_id: str)`: Executes multi-validator AI consensus audit.
- `claim_abandoned_trial_bond(claim_id: str)`: Reclaims bond after 7-day registry unreachability timeout.
- `decommission_uncontested_milestone(milestone_id: str)`: Decommissions terminal milestone.
- `withdraw_claimable()`: Reclaims uncollected balances safely.

### View Methods
- `get_milestone(milestone_id: str) -> dict`: Returns milestone record and parameters.
- `get_claim(claim_id: str) -> dict`: Returns claim status and adjudication verdict.
- `get_claimable_balance(account: str) -> u256`: Returns recoverable balance.
- `get_total_milestones() -> u256`: Returns total milestones created.
- `get_total_claims() -> u256`: Returns total claims filed.
- `get_total_volume_locked() -> u256`: Returns active TVL.

---

## 5. Verification & Regression Test Suite

The contract is validated via a 15-phase Python regression test suite:

```bash
python test/test_clinical_trial_audit_escrow.py
```

| Phase | Description | Result |
| :--- | :--- | :--- |
| **Phase 1** | Zero Genesis Invariants & Initial State | `PASSED` |
| **Phase 2** | Create Clinical Milestone with 100% Backed Funds | `PASSED` |
| **Phase 3** | Reserve Top-Up Recording | `PASSED` |
| **Phase 4** | SSRF Defense & Clinical Registry Whitelist | `PASSED` |
| **Phase 5** | Address Sanitation & Non-Zero Hex Enforcement | `PASSED` |
| **Phase 6** | Length-Prefixed Canonical Fingerprint Computation | `PASSED` |
| **Phase 7** | Clinical Endpoint Claim with Payable Bond | `PASSED` |
| **Phase 8** | Replay Defense on Duplicate NCT Trial Claims | `PASSED` |
| **Phase 9** | Consensus Adjudication: ENDPOINT_MET (p < 0.05) | `PASSED` |
| **Phase 10** | Consensus Adjudication: CLAIM_REFUTED | `PASSED` |
| **Phase 11** | Fail-Closed Web Evidence Ingestion Fallback | `PASSED` |
| **Phase 12** | 7-Day Timeout Dispute Bond Recovery | `PASSED` |
| **Phase 13** | Consensual Milestone Release by Sponsor | `PASSED` |
| **Phase 14** | Expired Unachieved Collateral Refund | `PASSED` |
| **Phase 15** | Pull-Pattern Recovery with Balance Preservation | `PASSED` |

---

## 6. Live Deployment & Explorer Verification

- **Contract Address**: `0x61AF74c41475b052a77087aAd0E3Ae79D0A577af`
- **Deployment Tx Hash**: `0x64bf9228127d93abb4811a9829b332495f591d1f1fddedf21db856f14e8233c5`
- **Network**: GenLayer Studio Testnet
- **Explorer URL**: [https://explorer-studio.genlayer.com/address/0x61AF74c41475b052a77087aAd0E3Ae79D0A577af](https://explorer-studio.genlayer.com/address/0x61AF74c41475b052a77087aAd0E3Ae79D0A577af)
- **RPC Endpoint**: `https://studio.genlayer.com/api`
